Edition:
India

3SBio Inc (1530.HK)

1530.HK on Hong Kong Stock

16.02HKD
19 Jan 2018
Change (% chg)

HK$-0.44 (-2.67%)
Prev Close
HK$16.46
Open
HK$16.46
Day's High
HK$16.58
Day's Low
HK$15.84
Volume
11,813,436
Avg. Vol
6,463,063
52-wk High
HK$17.90
52-wk Low
HK$7.26

Select another date:

Mon, Jan 15 2018

BRIEF-3Sbio Says Unit And Toray Sign Exclusive Licensing Agreement On Antipuritic Agent, TRK-820​

* UNIT AND TORAY ENTER EXCLUSIVE LICENSING AGREEMENT ON CERTAIN ORAL DISINTEGRATION TABLET FORMULATION OF ANTIPRURITIC DRUG TRK-820​ Source text for Eikon: Further company coverage:

BRIEF-3SBio Says ‍China FDA Approves New Once-Weekly Bydureon To Improve Glycemic Control​

* ‍CHINA FDA APPROVES NEW ONCE-WEEKLY BYDUREON TO IMPROVE GLYCEMIC CONTROL​ Source text for Eikon: Further company coverage:

BRIEF-3SBio Inc says 601a approved by China FDA for clinical trials ​

* Recombinant humanized anti-VEGF monoclonal antibody for injection (601a) approved by China FDA for clinical trials ​ Source text for Eikon: Further company coverage:

Chinese biopharma 3SBio in $290 million deal for unit of Canada's Therapure

SHANGHAI China's 3SBio Inc has agreed to buy the contract development and manufacturing unit of Canada's Therapure Biopharma Inc for $290 million, part of a push by the Chinese biotech company into the North American market.

Chinese biopharma 3SBio in $290 mln deal for unit of Canada's Therapure

SHANGHAI, Sept 4 China's 3SBio Inc has agreed to buy the contract development and manufacturing unit of Canada's Therapure Biopharma Inc for $290 million, part of a push by the Chinese biotech company into the North American market.

Select another date: